2.5 Definitions and endpoints
Neutrophil engraftment was defined as an absolute neutrophil count of
0.5 ×109/L or more for 3 consecutive days. Platelet
engraftment was defined as a platelet count of 20×
109/L or more for 7 consecutive days without
transfusion. Acute and chronic GVHD were diagnosed and graded according
to established criteria. Risk stratification was differentiated into two
groups: AML and ALL in first or second remission (CR1 or CR2), chronic
myeloid leukemia (CML) in the first or second chronic phase (CP1 or
CP2), and MDS with refractory anemia with or without ringed sideroblasts
were defined as the standard-risk group, and other malignant diseases
were defined as the high-risk group. Overall survival (OS) times were
measured from the date of HSCT until death from any cause. Leukemia-free
survival (LFS) was defined as the time from transplantation to relapse
or death from any cause. Surviving patients were censored on the date of
their last follow-up. Transplantation-related mortality (TRM) was
defined as death after allo-HSCT without disease progression or relapse.
Relapse was defined by the appearance of morphological evidence of the
disease obtained from testing samples from the peripheral blood, bone
marrow, or extramedullary sites or by recurrence and the sustained
presence of pretransplantation chromosomal abnormalities.